Should I Buy LNTH? LNTH 2026 Analysis

Should You Buy Lantheus Holdings Inc (LNTH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

64.890

1 Day change

0.05%

52 Week Range

111.290

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price is in a clear bearish trend (SMA_200 > SMA_20 > SMA_5) with negative/expanding MACD momentum.
Near-term risk skew is unfavorable: pattern-based projection implies elevated downside odds over the next week (-9.48% expected move in the model), and earnings are upcoming (2026-02-24 pre-market).
While options positioning is bullish (low put/call ratios), heavy insider and hedge fund selling plus deteriorated last reported profitability reduce confidence in an immediate rebound.
Intellectia signals do not provide a “strong buy now” override: AI Stock Picker = no signal; SwingMax = no recent signal.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), suggesting the dominant direction remains down.
Momentum: MACD histogram at -0.3 and negatively expanding, indicating downside momentum is strengthening.
RSI: RSI_6 ~37.1 (weak/near-oversold but not a reversal signal on its own).
Levels to watch: Pivot ~66.964 (price ~66.74 is just below pivot = weak). Support S1 ~65.291 then S2 ~64.257. Resistance R1 ~68.637 then R2 ~69.671.
Market context: S&P 500 down ~1.01% today, which can add pressure to a stock already trending bearishly.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call ratios are low (OI PCR 0.35; Volume PCR 0.2) which is typically bullish/positioned for upside.
Volatility: Implied vol (30D) ~58.39 vs historical vol ~21.93 (options pricing in large moves; can reflect uncertainty into earnings).
Activity: Today’s option volume ~100, about ~54.95% of 30-day average (not a spike in activity), with calls dominating (83 calls vs 17 puts).
Takeaway: Options lean bullish, but elevated IV suggests the market is paying up for protection/speculation (often ahead of catalysts like earnings).

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-24 (pre-market); a clean beat/raise could quickly re-rate sentiment.
- Analyst positioning is largely constructive (multiple Buys/Outperforms and higher targets in late 2025), implying Wall Street sees medium-term upside if growth re-accelerates.
- Options market positioning (very low put/call ratios) suggests traders are positioned more for upside than downside.

Neutral/Negative Catalysts

- Flow/positioning negative: Hedge funds are selling (selling amount +2127.26% last quarter) and insiders are selling aggressively (+5211.12% last month).
- Technicals are bearish: negative/expanding MACD and bearish moving-average stack increase probability of further drawdown before any durable bounce.
- Profitability deterioration in latest reported quarter (big YoY drops in net income, EPS, and gross margin) undermines the “buy now” case until trends stabilize.
- No supportive news flow in the last week (no fresh positive catalyst to reverse the tape).
- Political/influencer activity: No recent congress trading data available (no corroborating signal from that channel).

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $384.0M, +1.39% YoY (modest top-line growth).
Profitability: Net income $27.77M, -78.82% YoY; EPS $0.41, -77.09% YoY (sharp earnings compression).
Margins: Gross margin 57.91%, -9.42% YoY (meaningful margin deterioration).
Bottom line: The growth profile in Q3 was not strong enough to offset significant profitability/margin pressure, which aligns with the current weak technical setup.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Mostly positive revisions into late 2025 (Truist upgraded to Buy with an $80 PT; Mizuho raised PT to $72 and maintained Outperform; Truist raised PT to $82).
Most recent change: 2026-01-29 TD Cowen cut PT to $75 from $80 but maintained Buy (a mild tempering, not a thesis break).
Wall Street pros view: Bull case centers on expected FY27 growth/profit re-acceleration and catalysts driving durable revenue acceleration.
Wall Street cons view (implied by recent PT trim and current fundamentals): near-term uncertainty into results and the need to prove margin/profit recovery after the weak 2025/Q3 profitability print.

7 Analyst Rating

Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is 82.17 USD with a low forecast of 70 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 64.860

Low

Averages

82.17

High

105

Current: 64.860

Low

Averages

82.17

High

105

TD Cowen

Buy

downgrade

$80 -> $75

AI Analysis

2026-01-29

Reason

TD Cowen

Price Target

$80 -> $75

AI Analysis

2026-01-29

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Lantheus to $75 from $80 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.

Truist

Buy

maintain

$80 -> $82

2025-12-18

Reason

Truist

Price Target

$80 -> $82

2025-12-18

maintain

Buy

Reason

Truist raised the firm's price target on Lantheus to $82 from $80 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LNTH

Unlock Now

LNTH Should I Buy

LNTH Should I Buy

Should You Buy Lantheus Holdings Inc (LNTH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch